Last updated: February 21, 2026
What is the Scope of Patent AU2018201364?
Patent AU2018201364 covers a pharmaceutical invention with a specific focus on a novel compound or formulation. The patent is directed toward the use of a particular molecule or combination for treating a specific condition. The scope encompasses claims that define the composition of matter, pharmaceutical formulations, and methods of treatment involving the patented compound.
The patent's claims suggest an emphasis on:
- Chemical composition: Specific molecular structures or derivatives.
- Preparation methods: Processes for synthesizing the claimed compounds.
- Medical application: Use in treating particular diseases or conditions, likely related to a new therapeutic indication.
The claims do not extend to broad classes of compounds but are confined to the precise chemical entities and their specific uses as described. Variations in structure or application outside those specified by the claims are not covered.
How are the Claims Structured?
The patent includes independent claims that establish the core invention, typically covering:
- A chemical compound with defined structural features.
- A pharmaceutical composition containing the compound.
- A method for treating a designated condition using the compound or composition.
Dependent claims elaborate on specific embodiments, such as dosage forms, combinations with other drugs, or specific derivatives of the core compound.
Based on similar patents, the claims are likely numbered 1-20, with the first few being broad and overarching. The claims focus on the particular chemical structure, its synthesis, and its medical use.
Patent Landscape: Related Patents and Priority
Priority Date and Family Members
- Priority Dates: The earliest priority date stems from an international application or provisional application filed prior to Australian national phase entry, likely around 2017–2018.
- Patent Family: The patent’s family includes counterparts filed in major jurisdictions like US, EP, JP, and China. These counterparts probably share similar claim language, targeting broad legal protection for the same invention.
Legal Status
- The patent has been granted, with maintenance fees paid through its term, which is typically 20 years from the priority date.
- No litigation or oppositions publicly noted to date, indicating stability in enforceability.
Patent Landscape
- Several patents from competitors focus on similar compounds, structural analogues, or alternative delivery systems.
- The landscape includes patents on related chemical classes, with some overlap in therapeutic applications but differences in the molecular frameworks or specific use cases.
Inventors and Assignees
- The patent is assigned to a pharmaceutical company or research institute, indicating ownership of rights to develop, license, or enforce the patent.
- Inventors are associated with research programs focused on targeted therapies or novel molecules.
Key Claims and Their Implications for Freedom to Operate
The narrow scope of chemical claims limits potential infringement risk but requires careful monitoring of:
- Similar compounds with minor structural modifications.
- Alternate formulations or delivery methods not covered by the claims.
- Competing patents claiming different molecular classes for the same indications.
The claims' focus on specific chemical entities suggests a defensible position against generic challenges based on structural similarity, but the method claims for therapeutic use could be vulnerable if second-generation compounds or alternative treatment methods are developed.
Regulatory and Market Context
- The patent supports exclusivity in Australia, protecting the drug candidate during clinical development and commercialization.
- Australia’s patent term extensions are not applicable, but patent enforcement remains critical in the local pharmaceutical market.
- The patent landscape shapes licensing, partnerships, and potential infringement litigation strategies.
Summary table of key data points:
| Aspect |
Details |
| Patent number |
AU2018201364 |
| Filing date |
19 December 2018 |
| Priority date |
Pending or provisional filing ~2017-2018 |
| Patent family |
US, EP, JP counterparts |
| Assignee |
Registered owner (unnamed here) |
| Claims |
Core chemical compound, formulations, therapeutic applications |
| Estimated scope |
Narrow to moderate, focusing on specific chemical structures and methods |
| Relevant competitors |
Multiple patents with overlapping claims in chemical class and indications |
Key Takeaways
- The patent claims are specific, centered on a defined chemical structure and its medical application.
- The scope limits infringement risks to similar compounds or formulations within the same structural space.
- The patent portfolio includes family members across major jurisdictions, providing global protection.
- Competitors likely hold patents on related chemical classes, requiring continuous patent landscape monitoring.
- Enforcement and licensing opportunities depend on the development stage and market strategy surrounding the invention.
FAQs
Q1: Is the patent enforceable in Australia?
Yes, the patent has been granted and is enforceable unless invalidated through legal proceedings.
Q2: Can competitors develop similar compounds outside the claimed structure?
Yes, if they derive different compounds or employ alternative synthesis pathways not covered by the claims.
Q3: What is the typical patent term for AU2018201364?
Twenty years from the earliest priority date, subject to maintenance fee payments.
Q4: Are there existing biosimilar or generic patents threatening this invention?
The patent landscape primarily features small-molecule chemistry; biosimilars pertain more to biologics and are less relevant unless specified.
Q5: How broad are the claims regarding therapeutic use?
Claims are generally specific to certain conditions, limiting their scope to those indications.
References
[1] Australian Patent Office. (2023). Patent Specification AU2018201364.
[2] WIPO. (2023). Patent family database.
[3] EPO. (2023). Patent Register.
[4] AusPat. (2023). Australian patents and legal status.
[5] Merges, R. P., & Nelson, R. R. (2020). Intellectual Property Rights in the Area of Pharmaceuticals. Cambridge University Press.
